Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes.
Sphingosine-1-phosphate (S1P) induces a transient bradycardia in mammalian hearts through activation of an inwardly rectifying K(+) current (I(K(ACh))) in the atrium that shortens action potential duration (APD) in the atrium. We have investigated probable mechanisms and receptor-subtype specificity for S1P-induced negative inotropy in isolated adult mouse ventricular myocytes. Activation of S1P receptors by S1P (100 nM) reduced cell shortening by approximately 25% (vs. untreated controls) in field-stimulated myocytes. S1P(1) was shown to be involved by using the S1P(1)-selective agonist SEW2871 on myocytes isolated from S1P(3)-null mice. However, in these myocytes, S1P(3) can modulate a somewhat similar negative inotropy, as judged by the effects of the S1P(1) antagonist VPC23019. Since S1P(1) activates G(i) exclusively, whereas S1P(3) activates both G(i) and G(q), these results strongly implicate the involvement of mainly G(i). Additional experiments using the I(K(ACh)) blocker tertiapin demonstrated that I(K(ACh)) can contribute to the negative inotropy following S1P activation of S1P(1) (perhaps through G(ibetagamma) subunits). Mathematical modeling of the effects of S1P on APD in the mouse ventricle suggests that shortening of APD (e.g., as induced by I(K(ACh))) can reduce L-type calcium current and thus can decrease the intracellular Ca(2+) concentration ([Ca(2+)](i)) transient. Both effects can contribute to the observed negative inotropic effects of S1P. In summary, these findings suggest that the negative inotropy observed in S1P-treated adult mouse ventricular myocytes may consist of two distinctive components: 1) one pathway that acts via G(i) to reduce L-type calcium channel current, blunt calcium-induced calcium release, and decrease [Ca(2+)](i); and 2) a second pathway that acts via G(i) to activate I(K(ACh)) and reduce APD. This decrease in APD is expected to decrease Ca(2+) influx and reduce [Ca(2+)](i) and myocyte contractility.
Landeen
Lee K
LK
Department of Bioengineering, University of California, San Diego, La Jolla, California, USA.
Dederko
Dorothy A
DA
Kondo
Colleen S
CS
Hu
Betty S
BS
Aroonsakool
Nakon
N
Haga
Jason H
JH
Giles
Wayne R
WR
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000378:metabolism; D003864:Depression, Chemical; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000502:physiology; D006352:Heart Ventricles / Q000166:cytology / Q000187:drug effects; D066298:In Vitro Techniques; D008246:Lysophospholipids / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D015233:Models, Statistical; D009200:Myocardial Contraction / Q000187:drug effects*; D032383:Myocytes, Cardiac / Q000187:drug effects*; D024661:Potassium Channels, Inwardly Rectifying / Q000187:drug effects; D043562:Receptors, G-Protein-Coupled / Q000502:physiology; D049349:Receptors, Lysosphingolipid / Q000187:drug effects / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology
D020746:Calcium Channels, L-Type; D008246:Lysophospholipids; D024661:Potassium Channels, Inwardly Rectifying; D043562:Receptors, G-Protein-Coupled; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D013110:Sphingosine